Corient Private Wealth
ALLO icon

Corient Private Wealth’s Allogene Therapeutics ALLO Stock Holding History

Corient Private Wealth’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$85.5K Buy
+41,100
New +$90.3K ﹤0.01% 2954

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Corient Private Wealth's ALLO Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Allogene Therapeutics (ALLO) in Q2 2026: 41,100 shares worth $85.5K. The stake represents ﹤0.01% of the portfolio and ranks #2954 among its holdings.

209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Corient Private Wealth held 41,100 shares of Allogene Therapeutics worth $85.5K as of Q2 2026.
  • Allogene Therapeutics was a new Corient Private Wealth position in Q2 2026.
  • Allogene Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2954 holding.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.